Business
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of
About this update from Kala Bio, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.\n\n\nThe dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 5786176. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.\n\n\nAbout Kala Pharmaceuticals, Inc.\n\n\nKala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ MPP Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the August 2018 FDA approval of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product, EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, which is being studied for the temporary relief of the signs and symptoms of dry eye disease.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200206005178/en/\n\nInvestors:\nHannah Deresiewicz\[email protected]\n212-362-1200\n\nSource: Kala Pharmaceuticals, Inc.","length":2888,"tagName":"div"}]